Table 2.
Summary of primary and secondary outcomes
| Primary Outcomes, n (%) | |
|---|---|
| Appropriateness outcomes (n = 111) | |
| Appropriateness of indication | 106 (95.5) |
| Appropriateness of duration | 105 (94.6) |
| Clinical outcomes (n = 97) | |
| Clinical success | 70 (72.2) |
| Subsequent transition to oral amoxicillin-clavulanate | 54 (55.7) |
| Reason(s) for inability to transition to oral amoxicillin-clavulanate on day 3 of IV amoxicillin-clavulanate (n = 55) a | |
| Patient is not improving clinically | 29 |
| Inability to swallow | 9 |
| Pending specialist reassessment | 7 |
| Pending further workup of infection(s) or imaging | 7 |
| Patient non-compliant with oral medication | 2 |
| Nonfunctioning GI tract | 1 |
| Other | 4 |
| Reason(s) for re-escalation to piperacillin-tazobactam or a carbapenem (n = 27) | |
| Patients deteriorated clinically for the same indication | 18 (66.7) |
| Inadequate source control | 5 (18.5) |
| Grew subsequent resistant organisms | 3 (11.1) |
| A different infection developed | 1 (3.7) |
| Secondary outcomes ( n = 97), n (%) | |
| Hospital readmission | 15 (15.5) |
| Related to the same infection | 4 (26.7) |
| Readmitted for other reasons | 11 (73.3) |
| Mortality | 18 (18.6) |
| Comfort care/end of life | 12 (66.7) |
a
Does not add up to 55, as patient can have > 1 reason